Charles Schwab Investment Management Inc Monte Rosa Therapeutics, Inc. Transaction History
Charles Schwab Investment Management Inc
- $515 Billion
- Q3 2024
A detailed history of Charles Schwab Investment Management Inc transactions in Monte Rosa Therapeutics, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 346,498 shares of GLUE stock, worth $2.44 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
346,498
Previous 311,800
11.13%
Holding current value
$2.44 Million
Previous $1.17 Million
57.46%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding GLUE
# of Institutions
83Shares Held
43.9MCall Options Held
141KPut Options Held
31.2K-
Nea Management Company, LLC Timonium, MD7.69MShares$54.2 Million3.11% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.6MShares$46.5 Million0.0% of portfolio
-
Avoro Capital Advisors LLC New York, NY5.79MShares$40.8 Million0.46% of portfolio
-
Baker Bros. Advisors LP New York, NY4.92MShares$34.7 Million0.28% of portfolio
-
Suvretta Capital Management, LLC New York, NY2.66MShares$18.7 Million0.55% of portfolio
About Monte Rosa Therapeutics, Inc.
- Ticker GLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,713,900
- Market Cap $329M
- Description
- Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing prot...